Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Acquired by Monashee Investment Management LLC

Monashee Investment Management LLC increased its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 12.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 225,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. Structure Therapeutics makes up about 8.8% of Monashee Investment Management LLC’s holdings, making the stock its biggest position. Monashee Investment Management LLC’s holdings in Structure Therapeutics were worth $15,649,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in GPCR. Geode Capital Management LLC grew its stake in Structure Therapeutics by 18.5% in the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after acquiring an additional 8,444 shares during the period. Invesco Ltd. grew its stake in Structure Therapeutics by 7.6% in the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after acquiring an additional 30,162 shares during the period. Marshall Wace LLP grew its stake in Structure Therapeutics by 474.9% in the second quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after acquiring an additional 145,434 shares during the period. Jump Financial LLC grew its stake in Structure Therapeutics by 105.9% in the second quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after acquiring an additional 32,524 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in Structure Therapeutics in the second quarter valued at approximately $3,480,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Up 4.3%

GPCR stock opened at $43.30 on Friday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90. The stock’s 50 day moving average is $43.79 and its 200-day moving average is $57.28. The firm has a market capitalization of $3.08 billion, a PE ratio of -49.77 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on GPCR. HC Wainwright reduced their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday. Canaccord Genuity Group began coverage on Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective for the company. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.